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Abstract: Surgical treatment of brain cancer is limited by the inability of current imaging 
capabilities such as magnetic resonance imaging (MRI) to detect the entirety of this locally 
invasive cancer. This results in residual cancer cells remaining following surgery, leading to 
recurrence and death. We demonstrate that intraoperative Raman spectroscopy can detect 
invasive cancer cells centimeters beyond pathological T1-contrast-enhanced and T2-weighted 
MRI signals. This intraoperative optical guide can be used to detect invasive cancer cells and 
minimize post-surgical cancer burden. The detection of distant invasive cancer cells beyond 
MRI signal has the potential to increase the effectiveness of surgery and directly lengthen 
patient survival. 
© 2016 Optical Society of America 
OCIS codes: (170.5660) Raman spectroscopy; (170.1610) Clinical applications; (170.6935) Tissue characterization. 
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1. Introduction 
Grade 2-4 gliomas are primary brain cancers that invade into the surrounding normal brain 
but do not metastasize throughout the body. In contrast to well-circumscribed non-invasive 
primary brain tumors (grade 1 pilocytic astrocytomas) and secondary brain cancers 
(metastases), the boundaries of invasive gliomas are not detectable by MRI - the standard of 
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care imaging modality, intraoperative inspection, or any other technique. Two sets of 
contemporary data show that residual invasive glioma cells not resected at surgery decrease 
survival time. i) Eighty-five percent of grade 4 gliomas (glioblastomas) recur at the previous 
resection cavity margin [1]. ii) The volume of residual cancer is inversely proportional to 
survival time; patients with no post-operative MRI-detectable contrast-enhancing 
glioblastoma live more than 3 times longer than patients with greater than 1.5 cm of residual 
glioblastoma [2]. This inability to detect the entirety of an invasive glioma, in the absence of 
another suitable biomarker or curative adjuvant therapies, limits the utility of surgical 
treatment of this non-metastasizing cancer leading to a median recurrence time of 6 months 
and an overall survival time of 14.6 months [3,4]. 
With these detection deficiencies in mind, high performance practical optical approaches 
are being developed for enhanced cancer detection and guidance because of their molecular 
profiling capabilities [5]. We have shown that Raman spectroscopy (RS), a non-invasive 
label-free surface imaging modality that gives spectral information based on the vibrational 
and rotational modes of molecular species in tissue, can detect gliomas during surgery with a 
sensitivity of 93% and specificity of 91% [6]. 
Since MRI and existing surgical techniques are not capable of identifying the entirety of a 
glioma, we compared the invasive glioma sensitivity of MRI versus RS – can RS detect 
glioma cells that have invaded into the normal brain not detectable by MRI. Specifically, we 
tested the capability of RS to detect distant invasive glioma cells not detected using T1-
contrast-enhanced and T2-weighted MRI sequences in humans during brain cancer surgery. 
Extending our previous work in which we showed that RS can distinguish brain cancer from 
normal brain [6], we found that RS is able to intraoperatively detect invasive cancer not 
detectable using MRI. 
2. Methods 
2.1 Experimental design for intraoperative Raman spectroscopy 
The objective of this study was to investigate the capabilities of Raman spectroscopy (RS) for 
detecting invasive cancer beyond the signal visible on MRI. RS was used during brain tumor 
resection for N = 13 patients with grade 2-4 gliomas at the Montreal Neurological Institute 
and Hospital. The study was approved by the Montreal Neurological Institute Ethics Review 
Board, with informed consent obtained for all patients. The methods were carried out in 
accordance with the approved guidelines. A hand-held fiber optic probe (EmVision LLC, FL, 
USA) is connected to a 785 nm laser (Innovative Photonic Solutions, NH, USA) and a high-
resolution charge-coupled device spectroscopic detector (ANDOR Technology, Belfast, UK) 
(Fig. 1). There are seven inelastic scattering (RS) detection optical fibers, one laser excitation 
fiber, and a PC controls data acquisition with a LabVIEW interface. The diameter of the 
excitation fiber in the probe is 0.2 mm, and the diameter of the each of the 7 detection fibers 
is 0.3 mm. A lens is positioned in front of the optical fibers ensuring illumination and 
detection light paths are such that the tissue excitation area and the detection field-of-view are 
spatially coincident. The spatial area sampled by the probe is a circular spot size of diameter 
0.5 mm and a depth no larger than ~1 mm [6]. The acquired spectra range from Raman shifts 
of 381 to 1653 cm−1, and the spectral resolution varies between 1.6 and 2.1 cm−1. For each 
patient, the system was used to measure the Raman spectra at 5-15 locations during surgery. 
The probe was placed in direct contact with the brain at the resection cavity margin for each 
measurement, with a total acquisition time of 0.2 s per measurement. This corresponds to 
three Raman spectra measurements and one background measurement for reference with the 
excitation laser off. A StealthStation (Medtronic, MN, USA) was used to record the location 
of each measurement on preoperative MRI scans, by infrared tracking of fiducial markers 
fixed on the hand-held Raman spectroscopy probe. Superficial biopsy samples were taken at 
each measurement location for neuropathology analysis. 
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 Fig. 1. Experimental setup diagram with the hand-held fiber optic Raman probe connected to a 
785 nm NIR laser and high-resolution CCD spectroscopic detector. 
2.2 Neuropathological assessment 
Neuropathological analysis was performed by M.C.G., a neuropathologist with expertise in 
neuro-oncology. Cancer cells were identified on hematoxylin and eosin (H&E) stained 
sections. Cell counting was performed on H&E stained images to determine the cancer cell 
count per area. IDH1 (R132H) immunohistochemistry was also used to complement the H&E 
staining for cancer cell identification [6] (Fig. 2). 
 
Fig. 2. Images of neuropathology slides from tumor samples for 6 patients mutated for 
IDHR132H, corresponding to: (a) Anaplastic Astrocytoma (WHO grade 3); (b) Recurrent 
Oligodendroglioma (WHO grade 2); (c) Recurrent Astrocytoma (WHO grade 2); (d) 
Anaplastic Oligodendroglioma (WHO grade 3); (e) Anaplastic Astrocytoma (WHO grade 3); 
(f) Glioblastoma (WHO grade 4). 
2.3 Brain shift correction 
The comparison of visible tumor on preoperative MRI with RS measurement locations can be 
potentially affected by brain shift during surgery [7–9]. In order to minimize the effects of 
spatial registration errors, landmark locations were recorded during surgery on the cortical 
surface. These landmarks were compared with a reconstructed cortical surface from 
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segmented MR images in order to estimate brain shift. Moreover, the areas sampled in this 
study were primarily by white matter tracts near the midline which typically do not shift 
during surgery [9–11]. These areas are reinforced structurally by the fixed and rigid falx 
membrane that separates hemispheres. This diminishes any motion artifacts which may hinder 
neuronavigation. Moreover, the surgeon ensures that excess blood, water, or CSF is drained 
and/or regulated and samples are measured on relaxed intact tissue. Intracranial pressure and 
pulsatility are reduced, and the straining effect due to cerebral blood flow and brain swelling 
is diminished in tumor-invasive tissue. 
2.4 Tumor segmentation on preoperative MRI 
The preoperative MRIs were used to determine the boundary limits of cancer visible on T1-
contrast enhanced and T2-weighted sequences. All image processing was performed using the 
medical image segmentation and visualization tools in NIRFAST [12,13]. Semi-automated 
segmentation algorithms were used to identify the tumor region on MR images, and manual 
manipulation of the segmentation was used to further refine the result. While the exact 
segmentation process varied across patients due to differences in contrast and tumor structure, 
a description of the typical workflow for segmenting the tumor region follows. Figure 3 
shows an example of each step of the segmentation process. The MRI volume was first 
cropped down to the area around the tumor. Then a K-means and Markov random field 
algorithm was used to identify areas of similar grayscale values and structure in the remaining 
MRI volume (see the blue, yellow, and red regions in Fig. 3). The resulting region most 
accurately delineating the tumor area was kept, and all other regions discarded. A connected 
component algorithm was used to remove noise away from the tumor area. Iterative label hole 
filling was then used to remove any small holes in the segmentation. Finally, each slice of the 
MRI volume was examined to ensure that the segmentation identified all hyperintense regions 
of the tumor, with manual manipulation used to correct any errors in segmentation. Detailed 
descriptions of the segmentation algorithms can be found in previous work [12]. 
Segmentation was independently verified by Kevin Petrecca (neurosurgeon) and Mariam 
Alrashid (neurosurgeon). The measurement locations for RS were co-located on the T1- and 
T2-weighted MRI, which allowed for a comparison of the relative distance of these locations 
from the tumor segmentations. 
 
Fig. 3. This example shows the segmentation of a glioblastoma on T1-contrast enhanced (a) 
and T2-weighted (b) MRI. After cropping the MRI volume to the tumor area, semi-automated 
segmentation algorithms use grayscale values and structure to identify MR-enhancing areas 
corresponding to tumor. The final step (far right) shows the resulting tumor segmentation in 
red. 
2.5 Pre-processing and analysis of Raman spectroscopy data 
All spectra were pre-processed to subtract background reference spectra, normalize for laser 
power, and remove intrinsic tissue fluorescence using an iterative polynomial fit [14]. The 
boosted trees supervised machine learning algorithm was used to distinguish the spectra of all 
cancer tissue from normal brain. The algorithm uses an ensemble of decision trees based on 
                                                                 Vol. 7, No. 12 | 1 Dec 2016 | BIOMEDICAL OPTICS EXPRESS 5133 
training data to distinguish tissue types [15]. In the present work we are considering only the 
samples of normal brain and of invasive cancer. Namely, out of a total 128 measurements 
made for the N = 13 patients, only those associated with locations of normal brain (45 
measurements) or invasive cancer (60 measurements) were used. Samples were labelled 
invasive cancer if they had ≤90% cancer cells present. The classifier was used to distinguish 
the invasive cancer samples presented here from normal brain using leave-one-out cross-
validation. The total time for pre-processing and classification of a Raman spectrum was 
measured to be 0.068 s on a PC with an Intel i7-3770 CPU (3.40 GHz). Statistical analysis on 
classification accuracy was performed using two-sided normal-based 95% confidence 
intervals. Table 1 provides sample size and histological diagnosis for the patients. 
Table 1. Patient pathology and sample size information: A total of 60 invasive cancer 
samples were used, with a further 45 measurements of normal brain. 
  N patients n samples 
WHO grade 2  2 4 
 Astrocytoma 1 2 
 Oligodendroglioma 1 2 
WHO grade 3  4 12 
 Astrocytoma 2 5 
 Oligodendroglioma 1 1 
 Oligoastrocytoma 1 6 
WHO grade 4 Glioblastoma 7 44 
Total  13 60 
3. Results 
3.1 Intraoperative Raman spectroscopy during brain tumor resection 
The capability of RS to detect brain cancer cells that had invaded into the brain beyond the 
detection capability of MRI was assessed in thirteen patients with invasive grade 2-4 glioma. 
Surgical planning MRI data from each patient was used for 3-dimensional surgical 
navigational guidance [16,17] with a StealthStation navigation unit (Medtronic MN, USA). 
Surgeries were performed using standard microsurgical techniques. During surgery the 
suspected glioma boundary limits were identified based on navigational guidance, visual 
tissue properties, and tactile sensation of the tissue. Raman spectra were obtained at discrete 
points in these areas using the hand-held probe (Methods) in contact with tissue, with a 
circular laser spot of diameter 0.5 mm. The tissue at each interrogated point was collected and 
archived for post-surgical blinded neuropathological analysis (Table 1). These sites were also 
landmarked using the navigation system to allow for a direct comparison of the RS signal 
obtained versus the MRI signal at each site (Fig. 4(b)). 
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 Fig. 4. (a) Three-dimensional distances of invasive cancer samples (13 patients, n = 60 tissue 
samples) from the closest edge of visible tumor contrast on preoperative T1-contrast enhanced 
(top) and T2-weighted (bottom) MRI. The location of the invasive cancer samples was 
determined on preoperative MRI based on the StealthStation tracking system used during 
surgery. ‘Detected’ versus ‘Not Detected’ indicates which samples the classification algorithm 
was able to correctly identify as invasive cancer based on RS (true positive), and those which 
where misclassified (false negative), respectively. Note that the vertical axis is used only to 
provide separation of the data points to make the points with similar values on the horizontal 
axis more visible. (b) MRI images (from different patients) showing four sample RS 
measurement locations indicated by the red cross-hair: one coronal T1-contrast enhanced 
image for a patient with grade 3 anaplastic astrocytoma (left), followed by three axial T2-
weighted images, corresponding to patients with grade 4 glioblastoma, grade 3 anaplastic 
astrocytoma, and grade 4 glioblastoma, respectively. For each, the three-dimensional distance 
of the measurement location from T1-contrast enhanced or T2-weighted MRI contrast 
respectively is indicated. 
3.2 MRI tumor segmentation and neuronavigation 
To determine the relationship between the RS signal and the MRI signal representing glioma 
we reconstructed the MRI signal corresponding to the tumor in 3D within the brain using 
semi-automated segmentation algorithms. This technique generates a true correspondence 
between the T2-weighted and T1-contrast enhanced signals and the segmentation (Fig. 3). For 
each RS site interrogated the distance from that site and the nearest abnormal MRI signal 
obtained from the 3D cancer segmentations was calculated. As an example, Figs. 5(b)-5(e) 
shows the segmented tumor region for a patient with a glioblastoma on T1-contrast enhanced 
and T2-weighted MRI. The locations of the RS measurements for invasive cancer are shown 
relative to the tumor segmentations in Fig. 5(a). 
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 Fig. 5. (a) 3-Dimensional volume rendering from the preoperative MRI of a patient with a 
grade 4 glioblastoma. The tumor regions visible on T1- and T2-weighted MRI scans are 
indicated in red and blue respectively. White ‘plus’ symbols indicate measurement locations of 
invasive cancer detected with RS. (b) A T1-weighted MR axial image with the glioblastoma 
visible. (c) The same image as in b, with the segmentation of the tumor region visible in red. 
(d) A T2-weighted MR axial image with the glioblastoma visible, corresponding to the same 
cross section as in b and c. (e) The same image as in d, with the segmentation of the tumor 
region visible in blue. 
3.3 Raman spectroscopy tissue classification 
A supervised machine learning boosted trees classification algorithm [15] that utilizes all 
spectral data, rather than relying on specific spectral bands, was used to distinguish samples 
containing invasive cancer cells versus normal brain. We found that RS is able to detect 
distant invasive cancer cells up to ~3.7 cm beyond the T1-contrast enhanced MRI boundary 
and up to ~2.4 cm beyond the T2 MRI boundary (Fig. 4(a), N = 13 patients, n = 60 invasive 
cancer tissue samples). RS was able to detect invasive cancer with 92% accuracy, 92% 
sensitivity, and 93% specificity (two-sided normal-based 95% confidence intervals of < ± 
5%). The false negative rate was 8%, and the false positive rate was 7%. The corresponding 
RS signal and histopathology is shown in Fig. 6 for interrogated sites. Note that instrument 
response was not removed from the Raman spectra, and so several of the low-frequency 
features visible in the spectra will be associated with instrument response (especially 
associated with long-pass filters). This does not affect the ability to classify tissue using 
machine learning, since the instrument response is consistent throughout all measurements 
which were made with the same instrument. In this study we found that RS can detect as few 
as 6 cancer cells per 0.0625 mm2. 
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 Fig. 6. (a) Histopathology images for 4 tissue samples are shown: Three invasive grade 4 
glioblastoma samples and one normal brain sample from a patient with a grade 2 astrocytoma, 
corresponding to locations where RS were made. (b) Raman spectra of the measurement 
locations in a, with visible spectral differences. 
4. Discussion 
The appreciation that current imaging technologies, including standard of care MRI, cannot 
detect distant invasive brain cancer cells is critical because this limitation profoundly reduces 
the effectiveness of the surgical treatment of glioma. In fact this concept has been 
acknowledged for decades yet no substantial advances have been made [1,18–24]. Here, we 
demonstrate that RS can detect invasive cancer cells well beyond cancer detected on MRI in 
humans during surgery. RS detects invasive cancer up to ~3.7 cm and ~2.4 cm beyond T1-
contrast enhanced and T2 MRI boundary, respectively. 
This RS system is ideal for intraoperative glioma detection. It has a small footprint, rapid 
acquisition time, and is highly accurate. It can detect invasive cancer cells without disrupting 
the neurosurgical workflow and could complement or replace MRI-guided neuronavigation as 
a technique to identify cancer margins. This has potential to function as an intraoperative 
guide during brain cancer surgery, minimizing the number of cancer cells remaining 
following surgery. Imaging modalities such as positron emission tomography (PET), 
ultrasound (US), fluorescence-guided imaging, and optical coherence tomography (OCT) 
have been used for the detection of brain cancer, but with limited sensitivity and specificity 
for low-grade gliomas and invasive cancer [25–30]. Considering that 85% of glioblastomas 
recur at the previous resection cavity margin, RS-guided invasive cancer cell detection may 
increase the effectiveness of surgery and directly lengthen patient survival. 
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